slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 210,091-210,120
Pages 10,126
Rows per page 30
Component
210,091-210,120 of 303,780
05
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · OverviewLoop · So What Cascade1 hit
06
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Key TakeawaysLoop · Cost Of Inaction1 hit
07
Includes a waterfall-style chart showing debt components and a detailed table for debt and equity.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Capitalization Summary1 hit
08
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
09
Includes footnotes references (1) through (9) which are not explicitly rendered on this slide.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
10
The slide presents two separate tables for Sales and Marketing segments, detailing various add-backs and adjustments to arrive at Adjusted EBITDA.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
11
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
12
This is the fourth page of a four-part appendix disclosure regarding non-GAAP financial measures.Advantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations Beat · Appendix1 hit
13
Advantage Solutions | Results Presentation Deck | 13 slidesAdvantage Solutions | Results Presentation Deck | 13 slides · Advantage Solutions
Conference presentation Investor relations 1 hit
01
Includes company logo, tagline, date, and ticker symbol.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
04
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Golden Circle1 hit
05
The slide uses a Gantt-style chart to represent clinical trial progress for three distinct programs.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Golden Circle1 hit
06
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
07
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
08
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
09
Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the difficulty of treatment compliance.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem1 hit
10
The slide uses a pie chart for segmentation and a timeline/number line for diagnostic age, followed by key clinical metrics.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · AgitateLoop · Mece Breakdown1 hit
11
Includes a biological process diagram showing intracellular vs plasma metabolism.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · SolutionLoop · Mece Breakdown1 hit
12
The chart shows a clear dose-response relationship between 1.0 mg/kg and 10.0 mg/kg doses, with statistical significance marked at early time points.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
13
The slide uses two distinct chart types (Kaplan-Meier survival curve and a time-series pharmacodynamic plot) to demonstrate drug efficacy.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
14
The slide outlines a two-part clinical trial structure with specific cohorts and patient criteria.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
15
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
17
Includes a timeline-based progression of symptoms from infancy to adulthood.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
18
Aeglea BioTherapeutics | Investor Presentation Deck | 39 slidesAeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
19
Includes statistical significance markers and clinical guideline thresholds.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
20
Includes statistical significance (p-values) and MCID reference lines for GMFM-E.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
21
The slide uses a heatmap to visualize individual patient outcomes, a common technique in clinical trial reporting.Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
22
Data presented as n (%).Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit